Physician profile

Leon Peter

Largo, FL

NPI 1104528991

$708.39

in general payments reported to CMS, 2019-2025

7 companies · $670 in 2025

The $670 reported for 2025 was more than what 83% of providers received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$708.39

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Gilead Sciences, INC. $146.63 2025 Livdelzi
Boston Scientific Corporation $138.29 2025 Axonics
Bayer Healthcare Pharmaceuticals INC. $127.00 2025
Evoke Pharma, INC. $123.91 2025
Genzyme Corporation $119.01 2025
Amgen INC. $37.96 2024 Otezla, Enbrel
Ucb, INC. $15.59 2025 Bimzelx

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Leon Peter

$708.39

in general payments reported 2019-2025

Years
2024-2025
Top company
Gilead Sciences, INC.
Context
The $670 reported for 2025 was more than what 83% of providers received nationally.

https://glasscript.com/doctor/11919078/leon-peter

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.